title: Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
abstract: OBJECTIVE
  The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women.
  
  
  METHODS
  Eighty postmenopausal women affected by the metabolic syndrome were enrolled prospectively in the study and treated with diet plus supplementation of myo-inositol (2 g BID plus diet: intervention group) or with diet plus placebo (control group) for 6 months. They were evaluated at baseline and after 6 months for insulin resistance (homeostasis model assessment ratio [HOMA] insulin resistance), lipid profile, and blood pressure.
  
  
  RESULTS
  Myo-inositol plus diet improved systolic and diastolic blood pressure, HOMA index, cholesterol, and triglyceride serum levels with highly significant differences, compared with the groups treated only with diet and placebo. In the group treated with myo-inositol, a decrease in diastolic blood pressure (-11%), HOMA index (-75%), and serum triglycerides (-20%) and an improvement in high-density lipoprotein cholesterol (22%) were shown.
  
  
  CONCLUSIONS
  Supplementation with myo-inositol may be considered a reliable option in the treatment of metabolic syndrome in postmenopausal women.
authors.affiliation: Policlinico Hospital, Reggio di Calabria, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Giordano
authors.forename: Francesco
authors.initials: F
authors.lastname: Corrado
authors.forename: Angelo
authors.initials: A
authors.lastname: Santamaria
authors.forename: Simona
authors.initials: S
authors.lastname: Quattrone
authors.forename: Basilio
authors.initials: B
authors.lastname: Pintaudi
authors.forename: Antonino
authors.initials: A
authors.lastname: Di Benedetto
authors.forename: Rosario
authors.initials: R
authors.lastname: D'Anna
mesh_terms: D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D007294:Inositol / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D024821:Metabolic Syndrome / Q000178:diet therapy / Q000188:drug therapy*; D008875:Middle Aged; D017698:Postmenopause; D011446:Prospective Studies
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D007294:Inositol